Ankylosing Spondylitis Market Size & Growth Forecast 2026–2035, By Segments (Distribution Channel, Drug Class), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Ankylosing Spondylitis Market size was estimated at USD 6.42 Billion in 2025 and is projected to grow at a 6.5% CAGR from 2026 to 2035, reaching USD 12.05 Billion by 2035. The industry revenue for 2026 is calculated at USD 6.78 billion.

• Base Year Value (2025): USD 6.42 Billion
• CAGR (2026-2035): 6.5%
• Forecast Year Value (2035): USD 12.05 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Ankylosing Spondylitis Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 60.19% of the market in 2025, supported by broad specialist access, widespread biologic therapy use, earlier diagnosis, and consistent long-term disease management.
  • Asia Pacific is expected to grow at a 7.35% CAGR as expanding rheumatology services, improving healthcare infrastructure, and greater adoption of targeted therapies bring more patients into treatment pathways.

• Segment Momentum:

  • Hospital Pharmacy accounted for 50.67% of the market in 2025, supported by specialist-led treatment pathways, biologic dispensing, and integrated diagnosis and care within hospital settings.
  • NSAIDs are the fastest-growing drug class because they provide accessible symptom management, fit early-stage treatment needs, and support routine pain and stiffness control across a broad patient population.

• Market Expansion Drivers:

  • Rising prevalence of inflammatory autoimmune disorders increasing demand for targeted biologic therapies.
  • Advancements in IL-17 and TNF inhibitor biologics improving long-term disease management outcomes.
  • Growing adoption of biomarker-driven personalized treatment approaches enhancing therapeutic precision.

• Leading Market Participants:

  Key players in the ankylosing spondylitis market include AbbVie Inc. (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Johnson & Johnson (United States), Eli Lilly and Company (United States), Amgen Inc. (United States), UCB S.A. (Belgium), Merck & Co., Inc. (United States), Zydus Lifesciences Limited (India), Izana Bioscience Ltd. (United Kingdom).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 6.42 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 12.05 Billion by 2035
  • Growth Forecasts: 6.5% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Hospital Pharmacy (Distribution Channel) | TNF Inhibitors (Drug Class)
  • Emerging Opportunity Segment: Retail Pharmacy (Distribution Channel) | Non-Steroidal Anti Inflammatory Drug (NSAID) (Drug Class)

Market Growth Drivers and Industry Trends

Rising prevalence of inflammatory autoimmune disorders increasing demand for targeted biologic therapies

As diagnosis rates for chronic inflammatory autoimmune conditions rise, treatment pathways for the ankylosing spondylitis market are shifting more decisively toward targeted biologic therapies, especially for patients with persistent symptoms or inadequate response to conventional anti-inflammatory drugs. This trend is influencing prescribing behavior by moving rheumatologists earlier toward mechanism-specific options that can control inflammation more effectively and limit structural progression, while payers and providers increasingly recognize the long-term burden of unmanaged disease. The result is stronger demand for branded and follow-on biologics, supporting market expansion through sustained therapy use, specialist-led treatment escalation, and broader patient identification.

Advancements in IL-17 and TNF inhibitor biologics improving long-term disease management outcomes

Clinical progress in IL-17 and TNF inhibitor biologics is reshaping treatment expectations in the ankylosing spondylitis market by improving symptom control, functional mobility, and durability of response over extended treatment periods. These advances matter in practice because physicians are making therapy decisions with greater confidence around long-term disease suppression, while patients are more likely to remain on treatment when outcomes are more predictable and quality-of-life gains are meaningful. That dynamic is supporting market development by supporting biologic switching, earlier initiation in suitable patients, and continued uptake of differentiated products with clearer positioning in specialist care.

Growing adoption of biomarker-driven personalized treatment approaches enhancing therapeutic precision

The growing use of biomarker-informed treatment selection is making the ankylosing spondylitis market more clinically segmented, with therapy choices increasingly guided by likely response patterns rather than broad trial-and-error prescribing. In practice, this improves alignment between patient profile and mechanism of action, helping physicians choose among biologics with greater precision and reducing time lost on suboptimal treatment courses. That shift is increasing market penetration for advanced therapies by reinforcing confidence in targeted prescribing, sharpening product differentiation, and encouraging more individualized care strategies in rheumatology settings.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of inflammatory autoimmune disorders increasing demand for targeted biologic therapies	2.20%	High	North America, Europe	High	Near Term
Advancements in IL-17 and TNF inhibitor biologics improving long-term disease management outcomes	2.00%	High	North America, Europe	High	Mid Term
Growing adoption of biomarker-driven personalized treatment approaches enhancing therapeutic precision	1.70%	High	North America, Asia Pacific	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 60.19% share of the ankylosing spondylitis market in 2025, reflecting the region’s established diagnosis and treatment landscape for chronic inflammatory disorders. Its leadership is backed by broad access to specialist care, routine use of advanced biologic therapies, and a healthcare system that enables earlier identification and ongoing disease management. In practice, this sustains higher treatment uptake, more consistent monitoring, and stronger prescription volumes across branded therapies used in ankylosing spondylitis care.

Asia Pacific is projected to expand at a 7.35% CAGR over the forecast period, driven by improving access to rheumatology services and rising adoption of targeted therapies across major healthcare markets in the region. Growth in the ankylosing spondylitis market is being accelerated by increasing recognition of inflammatory spinal disorders, which is bringing more patients into formal treatment pathways, alongside expanding healthcare infrastructure that supports diagnosis, specialist referral, and long-term therapy initiation.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Emerging	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Supportive	Neutral	Restrictive	Neutral	Restrictive
Demand Drivers	Strong	Moderate	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Moderate	Sparse	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Strong	Stable	Weak

Key Country Insights

United States

Advanced Treatment Adoption

The U.S. ankylosing spondylitis market is characterized by continued use of advanced therapies, improved diagnosis pathways, and patient-focused disease management approaches. Healthcare providers are emphasizing targeted treatments and long-term monitoring strategies to address disease progression and improve quality of life.

Japan

Precision Rheumatology Care

Japan is strengthening ankylosing spondylitis management through improved diagnostic awareness and personalized treatment approaches. Healthcare providers are focusing on accurate assessment, appropriate therapy selection, and integration of advanced medicines into chronic disease care pathways.

South Korea

Biologic Therapy Expansion

South Korea’s ankylosing spondylitis market is influenced by increasing adoption of advanced biologic therapies and improved specialty care access. Healthcare stakeholders are emphasizing effective disease control, patient monitoring, and treatment strategies tailored to inflammatory arthritis management.

Germany

Specialist Care Integration

Germany’s ankylosing spondylitis market is supported by structured rheumatology care and adoption of biologic treatment approaches. Clinical practices are focusing on earlier disease recognition, coordinated patient management, and therapy optimization to improve outcomes for individuals with chronic inflammatory conditions.

France

Integrated Patient Management

France is developing ankylosing spondylitis care through coordinated rheumatology services and access to innovative treatment options. Healthcare providers are prioritizing early diagnosis, disease monitoring, and comprehensive management approaches to address long-term patient needs.

Italy

Clinical Care Optimization

Italy’s ankylosing spondylitis market is focused on improving clinical pathways and expanding access to advanced therapies. Rheumatology networks are emphasizing timely diagnosis, treatment personalization, and continuous disease management to support better patient outcomes.

Segment Leadership and Growth Trends

  Distribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Retail Pharmacy (Fastest-Growing Segment)

Hospital Pharmacy held the leading position in the ankylosing spondylitis market in 2025, accounting for a 50.67% share. This channel remains dominant because ankylosing spondylitis treatment often involves prescription biologics, specialist supervision, and structured hospital-based care pathways that support dispensing through hospital pharmacies. Its leadership is reinforced by the close connection between diagnosis, rheumatology consultation, treatment initiation, and medicine access within hospital settings, which keeps a large portion of the ankylosing spondylitis market anchored to this channel.

Retail Pharmacy is emerging as the fastest-growing distribution channel in the ankylosing spondylitis market as ongoing disease management increasingly shifts toward more accessible refill and maintenance models outside acute care settings. Growth is being supported by the practical need for convenience, repeat access, and broader patient reach, especially for therapies used over longer treatment durations. Compared with hospital-based dispensing, retail pharmacy gains momentum where patients and prescribers favor easier medicine pickup and continuity of access for established treatment regimens.

Drug Class Segment Analysis: TNF Inhibitors (Largest Segment) vs Non-Steroidal Anti Inflammatory Drug (NSAID) (Fastest-Growing Segment)

In 2025, TNF Inhibitors represented the largest drug class in the ankylosing spondylitis market with a 61.64% share. Their leadership reflects their established role in managing patients who require targeted control of inflammatory disease activity, particularly in treatment pathways where symptom burden and progression require more than basic pain relief. The segment’s strong position in the ankylosing spondylitis market is sustained by clinician familiarity, integration into specialist-led care, and their use in patients needing sustained therapeutic intervention.

Non-Steroidal Anti Inflammatory Drug (NSAID) is the fastest-growing drug class in the ankylosing spondylitis market, influenced by its practical role as an accessible and commonly used option for symptom management. The segment is gaining traction because it fits early-stage treatment needs and ongoing pain and stiffness control in a straightforward manner, making it relevant across a broad patient base. Relative to more advanced therapies, NSAIDs benefit from easier treatment adoption and routine use in day-to-day disease management, which supports faster growth.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Distribution Channel	Hospital Pharmacy, Retail Pharmacy, Others	Hospital Pharmacy	Retail Pharmacy
Drug Class	Non-Steroidal Anti Inflammatory Drug (NSAID), TNF Inhibitors, Others	TNF Inhibitors	Non-Steroidal Anti Inflammatory Drug (NSAID)

Competitive Landscape and Market Positioning

Top players in the ankylosing spondylitis market:

1. AbbVie Inc. (United States)

2. Pfizer Inc. (United States)

3. Novartis AG (Switzerland)

4. Johnson & Johnson (United States)

5. Eli Lilly and Company (United States)

6. Amgen Inc. (United States)

7. UCB S.A. (Belgium)

8. Merck & Co. Inc. (United States)

9. Zydus Lifesciences Limited (India)

10. Izana Bioscience Ltd. (United Kingdom)

Increasing focus on chronic inflammatory conditions is supporting advancements in targeted therapeutic development. Biological treatment approaches are improving disease management outcomes. The ankylosing spondylitis market is evolving with stronger emphasis on personalized and long-term treatment strategies.

Industry Development/News

Company Name	Date	Key Development
UCB	Mar-25	Received U.S. FDA approval for Bimzelx in treating ankylosing spondylitis and non-radiographic axial spondyloarthritis. This regulatory milestone significantly expands the drug's addressable patient population and bolsters UCB's competitive position in the immunology segment, following positive Phase III clinical data demonstrating sustained long-term efficacy and safety profiles for the treatment of axial spondyloarthritis indications.
UCB	Apr-25	Secured regulatory approval in South Korea for Bimzelx, authorized for use in ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. This approval facilitates the strategic expansion of UCB's immunology portfolio into the high-growth Asian market, reinforcing the company's objective to establish Bimzelx as a key therapeutic standard for chronic inflammatory diseases globally.
Alvotech and Teva Pharmaceutical Industries	Mar-25	Received U.S. FDA approval for SIMLANDI, an interchangeable high-concentration adalimumab biosimilar. The launch aims to compete directly in the large Humira market, providing a cost-effective, biosimilar alternative for ankylosing spondylitis patients. This approval enhances competitive pressure within the TNF-inhibitor space and offers providers greater flexibility for interchangeability in clinical treatment protocols.
Biocad	Apr-25	Advanced the commercialization of Seniprutug, a domestically developed ankylosing spondylitis treatment, with distribution reaching 45 Russian regions. By scaling the availability of this proprietary therapy, Biocad is strengthening its market position in Eastern Europe and demonstrating a shift toward localized production and distribution models for specialized biologics in the treatment of chronic autoimmune conditions.
Celltrion USA	Mar-25	Commercialized a low-WAC (wholesale acquisition cost) version of its adalimumab-aaty biosimilar. This strategic pricing initiative targets increased market adoption by improving affordability for patients with chronic conditions like ankylosing spondylitis. The move underscores the growing impact of biosimilar market entrants on the competitive landscape for reference-product immunology therapies and their role in optimizing healthcare expenditure.
Biocon Biologics	Apr-25	Launched Nepexto, an etanercept biosimilar to Enbrel, in the Australian market for autoimmune conditions including ankylosing spondylitis. This expansion highlights the company’s ongoing strategy to increase its global biosimilar footprint by entering key regulated markets and providing high-quality, lower-cost alternatives to established reference products, thereby altering the competitive dynamics of local rheumatology care.
Sandoz	Apr-25	Filed an antitrust lawsuit against Amgen, alleging the use of a "patent thicket" to prevent the U.S. market entry of the etanercept biosimilar Erelzi. This legal action highlights ongoing systemic barriers in the biologics market and underscores the high strategic stakes of protecting or challenging the lucrative revenue streams associated with long-standing reference products like Enbrel.
AbbVie	Apr-25	Expanded reimbursement coverage in South Korea for the JAK1 inhibitor Rinvoq. This policy update significantly improves patient access to advanced therapy for ankylosing spondylitis and other inflammatory conditions. The development strengthens AbbVie’s market share in the JAK inhibitor category by removing financial barriers to treatment for a broader segment of the patient population in the region.
Johnson & Johnson	Oct-24	Assumed full commercialization responsibility for Remicade and Simponi in the UK, previously managed by Merck Sharp & Dohme. This consolidation of the commercial footprint allows Johnson & Johnson to directly manage its immunology portfolio and optimize its market strategy for these established therapeutic agents used in the treatment of axial spondyloarthritis and other chronic inflammatory autoimmune conditions.
Pfizer	Apr-25	Announced that its infliximab biosimilar, IXIFI, became available in Canada. Approved for multiple indications including ankylosing spondylitis, this launch aligns with Pfizer's strategy to expand its biosimilar portfolio and provide more affordable biologic options, increasing the total availability of TNF-inhibitor treatments in the North American market.